MonTa Biosciences is a Clinical Stage Biotech Company with a vision to develop better cancer treatment to patients by utilizing the immune system to recognize and kill tumor cells, and ultimately build up an immune memory response that will protect the patient from metastatic disease.
MonTa Biosciences is advancing MBS8, a second-generation systemic TLR7 agonist designed to turn “Cold” tumors “Hot” and restore response to immunotherapy.
MBS8 has the unique selling points:
-
Phase I safety study completed with favorable safety and recommended dose established
-
Demonstrated tumor reductions in heavily pretreated solid tumor patients
-
Expansion study initiated in checkpoint-resistant melanoma (Denmark & Spain)
-
MBS8 differentiates versus first generation TLR7 agonist by improved efficacy and safety targeting immune cells after iv infusion
-
Designed to restore PD-1 responsiveness through innate immune activation
-
Positioned within a TLR7 field with strong clinical validation and capital momentum